ストックスクリーナーアプリを入手
31.33
0.23%
0.08
Catalyst Pharmaceuticals Inc (CPRX) 最新ニュース
Angelini Buyout And FIRDAPSE Settlement Reframe Catalyst Pharmaceuticals Story - Yahoo Finance
Angelini Pharma to buy Catalyst in deal worth $4.1 billion - MSN
Catalyst Pharmaceuticals Q1 earnings beat, Firdapse revenues rise Y/Y - MSN
Angelini Buyout And Firdapse Settlement Reframe Catalyst Pharmaceuticals Story - Sahm
CPRX Technical Analysis | Trend, Signals & Chart Patterns | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Catalyst Pharmaceuticals, Inc.Common Stock (NQ: CPRX - FinancialContent
CPRX Stock Price, Quote & Chart | CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) - ChartMill
Angelini Interest Puts Catalyst Pharmaceuticals Rare Disease Value In Focus - Sahm
Catalyst Pharmaceuticals: Angelini Deal Caps A Potentially Better Story (NASDAQ:CPRX) - Seeking Alpha
CPRX SWOT Analysis: Strong Financials Amidst Market Challenges R - GuruFocus
Catalyst Pharmaceuticals (CPRX) Q1 EPS Beat Reinforces High Margin Bull Narratives - Sahm
Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - Yahoo Finance
Trading the Move, Not the Narrative: (CPRX) Edition - Stock Traders Daily
Catalyst Pharmaceuticals earnings beat by $0.06, revenue topped estimates - Investing.com Canada
Catalyst Pharmaceuticals (CPRX) Announces Suspension of Guidance Updates - GuruFocus
Catalyst Pharmaceuticals, Inc. Q1 2026 earnings preview - MSN
CPRX Reports Impressive Q1 Revenue Growth - GuruFocus
Catalyst Pharma Reports Higher Revenue, Suspends Earnings Guidance - TipRanks
Catalyst Pharmaceutical (CPRX) Surpasses Q1 Earnings and Revenue Estimates - Yahoo Finance
Catalyst Pharmaceuticals 1Q EPS 50c >CPRX - Moomoo
Profit rises at Catalyst Pharmaceuticals (NASDAQ: CPRX) on Q1 2026 results - Stock Titan
Catalyst Pharmaceuticals Q1 Adjusted Earnings, Revenue Rise - marketscreener.com
Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results - The Manila Times
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Reports Q1 Revenue $149.4M, vs. FactSet Est of $149.5M - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, vs. FactSet Est of $0.65 - marketscreener.com
Earnings Flash (CPRX) Catalyst Pharmaceuticals, Inc. Posts Q1 Adjusted EPS $0.79 per Share, Vs. FactSet Est of $0.65 - Moomoo
BRIEF-Catalyst Pharmaceuticals Q1 Revenue USD 149.4 Million Vs. IBES Estimate USD 148.2 Million - TradingView
Catalyst Pharma (NASDAQ: CPRX) posts Q1 profit ahead of Angelini deal - Stock Titan
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) Scores 7/10 Fundamental Rating in Affordable Growth Screen - ChartMill
Angelini Pharma agrees $4.1bn Catalyst Pharmaceuticals acquisition - Yahoo Finance
Catalyst Pharmaceuticals (CPRX) Set to Report Q1 Earnings with P - GuruFocus
Catalyst FIRDAPSE Deal Extends Exclusivity To 2035 And Shapes Angelini Bid - Sahm
Catalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - The AI Journal
Vanguard Group Inc. Lowers Position in Catalyst Pharmaceuticals, Inc. $CPRX - MarketBeat
Catalyst Pharmaceuticals Buyout And FIRDAPSE Patents Reframe Investor Outlook - Yahoo Finance
Angelini Pharma to buy Catalyst Pharmaceuticals for $4.1B - MSN
Family-run Angelini Pharma buys Catalyst Pharmaceuticals for over 4 billion - MSN
FinancialContentCatalyst Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Catalyst Pharmaceuticals, Inc.CPRX - FinancialContent
Catalyst Pharmaceuticals Cut to Neutral From Buy by Citigroup - Moomoo
MSN Money - MSN
Citigroup downgrades Catalyst Pharmaceuticals (CPRX) - MSN
Catalyst Pharmaceuticals (NASDAQ:CPRX) Lowered to "Hold" Rating by Robert W. Baird - MarketBeat
CPRX Downgraded by Citigroup -- Price Target Lowered to $31.50 - GuruFocus
Citi Downgrades Catalyst Pharmaceuticals(CPRX.US) to Hold Rating, Cuts Target Price to $31.5 - Moomoo
European company to acquire Miami pharma business for $4.1 billion - The Business Journals
Oppenheimer Downgrades Catalyst Pharmaceuticals to Market Perform From Outperform - Moomoo
Angelini Pharma acquires Catalyst Pharmaceuticals for $4.1 billion - Yahoo Finance
Catalyst Pharmaceuticals stock (US14888U1016): Angelini Pharma to buy CPRX for $4.1 billion in cash - AD HOC NEWS
Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease - Mynewsdesk
0.06%
0.47%
大文字化:
|
ボリューム (24 時間):